Skip to content
HowShorted

Axsome Therapeutics, Inc. short interest in 2022

In 2022, Axsome Therapeutics, Inc.'s disclosed short interest ran from 8.84% of shares outstanding on 14 Jan 2022 to 17.38% on 30 Dec 2022, a change of +8.54 percentage points. The year's high was 18.26% on 30 Nov 2022 and its low 8.84% on 14 Jan 2022, averaging 13.52% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.35 days on 30 Dec 2022. Full history: Axsome Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Axsome Therapeutics, Inc. in 2022

2022 in figures

Start of year
8.84% (14 Jan 2022)
End of year
17.38% (30 Dec 2022)
Change
+8.54 pp
High
18.26% (30 Nov 2022)
Low
8.84% (14 Jan 2022)
Average
13.52%
Highest days to cover
9.35 (30 Dec 2022)
SEC filings marked
8

Every report in 2022

Axsome Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20228.84%6.67
31 Jan 20229.19%4.33
15 Feb 20229.98%5.45
28 Feb 202211.73%6.87
15 Mar 202211.98%6.1410-K filed, results (8-K)
31 Mar 202212.68%5.89
14 Apr 202212.10%6.55
29 Apr 202211.62%1.88
13 May 202212.52%4.1610-Q filed, results (8-K)
31 May 202212.81%6.34
15 Jun 202213.45%7.69
30 Jun 202214.30%1.41
15 Jul 202215.36%4.96
29 Jul 202214.78%7.93
15 Aug 202213.55%6.1010-Q filed
31 Aug 202214.69%1.63results (8-K)
15 Sep 202214.15%5.66
30 Sep 202213.89%4.45
14 Oct 202214.23%4.32
31 Oct 202214.35%5.76
15 Nov 202215.63%3.6910-Q filed, results (8-K)
30 Nov 202218.26%3.65
15 Dec 202216.98%6.35
30 Dec 202217.38%9.35

See also: Axsome Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.